#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Cardiomyopathy Anti-glomerular basement membrane disease Selective polysaccharide antibody deficiency Rheumatoid arthritis Leukocyte adhesion deficiency type I Cerebral amyloid angiopathy CDKL5 deficiency disorder Adenomatous polyposis coli Squamous cell carcinoma of head and neck Neoplasm malignant Haemophilia Muscular dystrophy Urea cycle disorder Crohn's disease Non-renal cell carcinoma of kidney More trials…

    Learn about Rare Diseases

    Mitochondrial myopathy – Basic Information Pemphigoid – Basic Information Loeys-Dietz syndrome – Diagnostics Erdheim-Chester disease Gaucher’s disease type III – Diagnostics Pleural mesothelioma malignant – Trials in Disease Usher’s syndrome – Trials in Disease Breast angiosarcoma – Treatment Sarcoidosis Metachromatic leukodystrophy – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    L-Arginine Hydrochloride Baricitinib Benzocaine Rigosertib Sodium Norucholic Acid Brentuximab Vedotin Clodronate Disodium Salbutamol Sulfate Ph. Eur. AZD4360 ARTICAINE HYDROCHLORIDE Ucp2 Atomoxetine Hydrochloride Lamotrigine Lysine Hydrochloride Raltegravir Hyoscine Butylbromide IM-101 VELPATASVIR Transcon Il-2Β/Γ Gsk4004280 More therapies…

    Learn about Your Condition

    Post-traumatic headache Metastatic glioma Peripheral artery stenosis Diverticulitis High-grade B-cell lymphoma Follicular lymphoma stage III Salivary gland cancer Endometrial cancer Pneumonia bacterial Systemic mastocytosis Arterial tortuosity syndrome Neurogenic bladder Arrhythmia Thymic carcinoma Vascular graft thrombosis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Nervous System Diseases

  • Study on Personalized Dosing of Natalizumab for Patients with Relapsing-Remitting Multiple Sclerosis

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Multiple sclerosis
    Investigated Drugs:
    • Natalizumab
    The Netherlands

  • Study on the Effects of Lamivudine on Cognitive Impairment in Patients with Mild Cognitive Impairment Due to Alzheimer’s Disease

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Cognitive disorder
    • Dementia Alzheimer’s type
    Investigated Drugs:
    • Lamivudine
    Spain

  • Study on Fenebrutinib for Patients with Relapsing Multiple Sclerosis

    Not recruiting

    2 1
    Investigated Diseases:
    • Relapsing multiple sclerosis
    Croatia Czechia Slovakia

  • Study on the Effectiveness and Safety of NT 201 (Botulinum Toxin) for Treating Lower Limb Spasticity in Adults After Stroke or Traumatic Brain Injury

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Paresis
    Investigated Drugs:
    • Clostridium Botulinum Neurotoxin Type A (150Kd), Free Of Complexing Proteins
    Belgium Czechia France Germany Hungary Italy +3

  • Study on Rimegepant for Treating Migraine in Adults Who Cannot Use Triptans

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Migraine
    Investigated Drugs:
    • Rimegepant
    Austria Belgium Denmark Finland France Germany +4

  • Study on Rimegepant for Preventing Migraines in Adults with Poor Response to Oral Preventive Medications

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Migraine
    Investigated Drugs:
    • Rimegepant
    Austria Belgium Denmark Finland Germany Italy +3
Previous Page
1 … 97 98 99 100 101 … 142
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!